Roffman Miller Associates Inc. PA Sells 5,321 Shares of Albemarle Co. (NYSE:ALB)

Roffman Miller Associates Inc. PA trimmed its position in shares of Albemarle Co. (NYSE:ALB) by 9.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 48,681 shares of the specialty chemicals company’s stock after selling 5,321 shares during the period. Roffman Miller Associates Inc. PA’s holdings in Albemarle were worth $4,190,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Primecap Management Co. CA raised its holdings in shares of Albemarle by 0.5% during the 3rd quarter. Primecap Management Co. CA now owns 3,833,984 shares of the specialty chemicals company’s stock worth $363,117,000 after acquiring an additional 20,930 shares in the last quarter. Geode Capital Management LLC increased its stake in Albemarle by 0.5% in the 3rd quarter. Geode Capital Management LLC now owns 2,741,906 shares of the specialty chemicals company’s stock worth $258,797,000 after buying an additional 14,874 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Albemarle by 38.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,020,590 shares of the specialty chemicals company’s stock valued at $96,660,000 after purchasing an additional 282,194 shares during the period. Manning & Napier Advisors LLC bought a new stake in shares of Albemarle in the fourth quarter valued at about $85,570,000. Finally, Empower Advisory Group LLC boosted its stake in shares of Albemarle by 5.1% during the fourth quarter. Empower Advisory Group LLC now owns 741,484 shares of the specialty chemicals company’s stock valued at $63,827,000 after purchasing an additional 35,765 shares in the last quarter. Institutional investors own 92.87% of the company’s stock.

Analysts Set New Price Targets

ALB has been the subject of a number of recent research reports. KeyCorp reduced their target price on shares of Albemarle from $127.00 to $122.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Morgan Stanley dropped their target price on Albemarle from $73.00 to $68.00 and set an “underweight” rating on the stock in a research report on Tuesday, February 18th. Deutsche Bank Aktiengesellschaft reduced their price objective on Albemarle from $109.00 to $105.00 in a research note on Wednesday, February 12th. Piper Sandler dropped their price target on shares of Albemarle from $90.00 to $85.00 and set an “underweight” rating on the stock in a research report on Thursday. Finally, Truist Financial dropped their price target on shares of Albemarle from $96.00 to $85.00 and set a “hold” rating on the stock in a research note on Friday, February 14th. Two analysts have rated the stock with a sell rating, fifteen have given a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $109.68.

Insider Transactions at Albemarle

In other Albemarle news, CEO J Kent Masters sold 2,525 shares of Albemarle stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $101.12, for a total value of $255,328.00. Following the transaction, the chief executive officer now owns 73,747 shares in the company, valued at $7,457,296.64. This trade represents a 3.31 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.38% of the company’s stock.

Albemarle Stock Down 1.5 %

Albemarle stock opened at $81.26 on Monday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.19 and a current ratio of 1.95. The firm has a market capitalization of $9.55 billion, a price-to-earnings ratio of -7.26, a price-to-earnings-growth ratio of 45.02 and a beta of 1.59. The stock’s fifty day moving average is $86.93 and its two-hundred day moving average is $92.23. Albemarle Co. has a fifty-two week low of $71.97 and a fifty-two week high of $143.19.

Albemarle (NYSE:ALB) last issued its quarterly earnings data on Wednesday, February 12th. The specialty chemicals company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.49). Albemarle had a negative net margin of 21.93% and a negative return on equity of 1.72%. Analysts predict that Albemarle Co. will post 0.11 EPS for the current fiscal year.

Albemarle Profile

Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Energy Storage, Specialties and Ketjen. The Energy Storage segment offers lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services.